A few weeks ago, Hyderabad-based Biological E made headlines by becoming the second created-in-India vaccine player with the government announcing an advance of Rs 1,500 crore for 300 million doses of its candidate Corbevax, which is awaiting the drug regulator’s approval. This order is part of a larger vaccine plan by this 73-year-old company, currently the world’s largest producer of tetanus vaccines.
The sheer volumes could make Biological E, considered a dark horse in the business, a game-changer, more so because Corbevax is not its only bet. Last year, Mahima ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU